Close menu

September 11th, 2020 | 09:59 CEST

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19
Photo credits:

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.

time to read: 3 minutes | Author: Mario Hose
ISIN: CA91915B1085 , US09075V1026 , NL0015436031

Table of contents:

    VALEO PHARMA INC - Growth strategy with profit margin

    The Canadian specialty pharmaceutical company Valeo Pharma is focused on commercialization of innovative prescription products in Canada. With a focus on neurodegenerative diseases, oncology products and specialty products for hospitals, Valeo Pharma claims to have a growing portfolio of innovative products and a mature infrastructure that enables it to manage these products properly through all stages of commercialization.

    Valeo Pharma therefore offers investors the advantage that the company does not carry out its own research or development and therefore does not have to incur high costs before bringing products to market. The company collaborates with other pharmaceutical companies specializing in research into active ingredients and therapies. In connection with the current Corona pandemic, the company and its partner Ingenew have successfully launched Hesperco's market introduction in Canada and are now taking care of the commercialization of the product.

    Pierre Laurin, CEO of Ingenew, explained the importance of the compound in a press release: "There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system and potentially fight off symptoms associated with Corona viruses such as the one that causes COVID-19. Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidate to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)“

    In order to increase its own growth and the marketing of its products, Valeo Pharma has successfully completed an equity financing of CAD 6.9 million. "We are very pleased to have completed this bought deal financing with strong investor demand from a broad base of new shareholders. The proceeds of this financing will be used to support the launch of several new products in the coming months and to accelerate new growth opportunities," said Steve Saviuk, CEO of Valeo Pharma.The advantage of the company is that access to physicians can be used more intensively with a growing and high-margin product portfolio - without research risks.

    BIONTECH SE ADR - Preparations are in full swing

    The German biotechnology company BioNTech was able to attract public attention through its collaboration with the US pharmaceutical giant Pfizer shortly after the outbreak of the Corona pandemic. In the meantime, the company is one of the hopefuls in the fight against the spread of Covid-19. A further collaboration with another company now makes it clear that the availability of a vaccine is becoming increasingly likely in the near future.

    Yesterday, BioNTech together with the German pharmaceutical company Dermapharm announced that the two companies will cooperate in the production of the Covid-19 vaccine. According to the announcement, the capacities will be available right from the start of vaccine production, and if the vaccine is approved quickly, up to 100 million units will be produced worldwide this year, and then a total of 1.3 billion units by the end of 2021.

    CUREVAC NV - Further government research funds

    Another German biotech company is also leading the race for an effective corona vaccine. In recent weeks, CureVac was not only able to announce a successful IPO and the visit of Elon Musk, but the Federal Ministry of Research has promised the company up to a further EUR 252 million for the development of a vaccine.

    From France, the pharmaceutical group Sanofi has already made a statement about a possible price for a vaccine. According to Sanofi President Olivier Bogillot, the price of a Sanofi vaccine will be less than EUR 10 per dose. It is already clear, regardless of who wins the race, that the pharmaceutical industry has undergone a significant change and will benefit in the long term from increased efficiency in the development of active ingredients. Patients will also be able to benefit from the competitive situation and the potential product diversity.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Related comments:

    Commented by Mario Hose on January 14th, 2022 | 12:17 CET

    Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus

    • Covid-19

    At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.


    Commented by Mario Hose on January 13th, 2022 | 18:11 CET

    New research results for Covid-19: BioNTech, Cardiol, Valneva

    • Covid-19

    In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.


    Commented by Mario Hose on January 12th, 2022 | 10:53 CET

    Trading stocks after EMA warning in focus: BioNTech, Johnson + Johnson, Moderna

    • Covid-19

    On Wednesday, the German indices began with a positive sign. The German benchmark index DAX is currently quoted at a level of 16,004 points and thus around 0.04% slightly up. The companies in the second tier can also hold their ground and the MDAX last traded at 34,864 points (+0.26%), TexDAX at 3,644 points and thus 0.60% lower than the previous day. SDAX also loses and last traded at 15,969 points (-0.23%).